



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 11246

Title: Focus on emerging drugs for treatment of patients with non-alcoholic fatty liver disease

Reviewer code: 01490291

Science editor: Ya-Juan Ma

Date sent for review: 2014-05-11 21:26

Date reviewed: 2014-06-04 22:50

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

the authors wanted to make an up -to-date on the treatment of NAFLD / NASH with particular attention to the emerging drugs , the work is worth publishing . to that end, here are some tips before the final acceptance : Section 3.1: add one or more examples of the unresolved issues rigurado this approach Section 3.2 . the section regarding the vitamin E should be moved to homogeneity ' in section 6.2 Section 6 the sequence of cytoprotective agents must be reversed according to the sequence 6.1 6.2 (UDCA before and after antioxidants) Section 7.1 would add a statement on documented altered intestinal permeability as evidenced by Miele et al , Hepatology. 2009 Jun;49(6):1877-87. (add this bibliography) Section 7.3: add the bibliography citation of previous studies regarding the role of the renin angiotensin system Finally, the title of Table 2 must be completed with the object of the meta-analysis and the reference number of the final bibliography



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 11246

Title: Focus on emerging drugs for treatment of patients with non-alcoholic fatty liver disease

Reviewer code: 00006552

Science editor: Ya-Juan Ma

Date sent for review: 2014-05-11 21:26

Date reviewed: 2014-06-07 14:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review summarizes current pharmacological therapy for NASH, and the discussed studies are well-balanced and current. However, there are a number of issues need to be addressed: 1. To help readers to have a solid message after each section, a brief summary or bullet points should be provided. 2. Many anti-oxidants are included in 6.2 Anti-oxidants and Herbal Anti-Oxidants Products. A table should be given for comparison of property of agents, efficacy, side effects and study design, etc. 3. Table 1 is less informative and a better design of the table with more information is needed for a comprehensive overview. 4. A number of linguistic defects are identified, including misspelling, tense, etc. A careful linguistic revision and polishing will guarantee the quality of this review article. 5. For obeticholic acid, a late clinical trial published in Gastroenterology 2013 should be discussed.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 11246

Title: Focus on emerging drugs for treatment of patients with non-alcoholic fatty liver disease

Reviewer code: 02541391

Science editor: Ya-Juan Ma

Date sent for review: 2014-05-11 21:26

Date reviewed: 2014-06-08 08:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Major point: The article is suitable for publication after deeply revising the language, grammar, some inconsistencies in the References section, as well as some assertions, inconsistent with the references.

Specific comments: some affirmations are not consistent with the references: a) Section 4.2 "Exenatide, when compared with metformin, is better to control blood glucose values, improves body weight and ameliorates hepatic enzymes and histological features of steatosis in patients with NAFLD concomitant to T2DM [54]". However, liver histology was not performed in the study conducted by Fan H et al (please see Fan H et al, ref. 54). b) Table 1 - the title should be reviewed because it does not fully reflect the table contents ("...actually proposed" and "Emerging drugs and new horizons" - the safety and tolerability of these drugs are currently being evaluated); c. In each section, small paragraphs can be dedicated to the conclusions.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 11246

Title: Focus on emerging drugs for treatment of patients with non-alcoholic fatty liver disease

Reviewer code: 00058441

Science editor: Ya-Juan Ma

Date sent for review: 2014-05-11 21:26

Date reviewed: 2014-06-10 15:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This manuscript is well written and covered up-to-date information regarding potential therapeutics for NASH/NAFLD. I recommend this manuscript to be published in our journal.